Table 5 Treatment-related AEs in the placebo-controlled study of Wu et al [56]
Adverse events | Placebo | BTX-A |
|---|---|---|
(n = 20) | (n = 22) | |
Transient facial asymmetry | 0 | 5 (23%) |
Transient edema | 1 (5%) | 2 (9%) |
Adverse events | Placebo | BTX-A |
|---|---|---|
(n = 20) | (n = 22) | |
Transient facial asymmetry | 0 | 5 (23%) |
Transient edema | 1 (5%) | 2 (9%) |